3rd Liquid Biopsy Surveillance Summit

Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive the most effective and safe treatments. In 2024, a wave of collaborations has surged, propelling the use of liquid biopsies for MRD testing to new heights. The FDA's recognition of MRD as an endpoint in multiple myeloma marks a monumental leap forward for the field, heralding a new era in patient care and therapeutic development.

The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision treatments.

Expect to hear critical insights from leading biopharma, oncologists and diagnostic providers to utilise liquid biopsies as surrogate endpoints in clinical trials, guide dosing decisions and enable the development of precise drugs for patients with unmet needs in oncology and beyond.

Join your peers from Biomarker, Translational and Clinical Development teams to more accurately monitor drug response through MRD assessments for improved treatment regimens from early to late stage clinical trials to improve patient outcomes.

URLs:
Website: https://go.evvnt.com/2612043-0?pid=10018
Tickets: https://go.evvnt.com/2612043-2?pid=10018
Brochure: https://go.evvnt.com/2612043-3?pid=10018

Prices:
Drug Developer and Researchers - Conference Only: USD 0.50,
Solution Providers - Conference Only: USD 3699.00

Speakers: Angela Silvestro, Director - Companion Diagnostics, GSK, David Yu, Director - Precision Medicine and Translational Medicine, Bristol Myers Squibb, Gabriele Allegri, Vice President - Global Commercial Precision Medicine, Johnson and Johnson Innovative Medicine, J.D. Schonhoft, Associate Director - Translational Medicine, Repare Therapeutics, Janet Jin, Executive Director - Precision Medicine, Clinical Diagnostics and Imaging, Amgen, Jean-Francois Martini, Executive Director - Translational Oncology Lead, Global Product Development - Oncology, Pfizer, Jessica Piel, Senior Director and Head - Translational Sciences, Foghorn Therapeutics, Jonathan Beer, Senior Director - Diagnostic Sciences, Bristol Myers Squibb, Judy Keen, Director - Translational Science, Cancer, Foundation for the NIH, Kris Sachsenmeier, Vice President - Head of Translational Sciences, Lauren Leiman, Executive Director, BLOODPAC, Minakshi Guha, Associate Director - Precision Medicine, Companion Diagnostics and Liquid Biopsy Lead, Takeda, Miriam Colindres Rojas, Associate Director - Diagnostics and Analytics Strategy, BioNTech, Nisha Rajagopal, Associate Director - Data Science, Novartis, Piero Ricchiuto, Head of Clinical Bioinformatics and Biomarker Discovery, Alexion Pharmaceuticals, Raluca Budiu-Predoiu, Director - Precision Medicine, AbbVie, Shou-Ching Jaminet, Co-Founder, Angiex, Simon Heeke, Assistant Professor - Head of Liquid Biopsy Translational Working Group, MD Anderson Cancer Center, Xintong Chen, Director - Translational Medicine Strategy, AstraZeneca, Yinghui Zhou, Head - Translational Science, Synnovation Therapeutics, Zheng Feng, Director and Head - Clinical Genomics Clinical Biomarker Technologies, EMD Serono